Community curated by people like you

Escherichia coli stories

Nov 10, 2026

AstraZeneca acquires vaccine biotech Omniose to bolster pipeline

AstraZeneca acquired early-stage US biotech Omniose, which is developing vaccines against serious bacterial infections, integrating it into its infectious diseases division.

Nov 10, 2026·2 sources

00

Top claims

▪Bioconjugation streamlines conjugate vaccine manufacturing compared to traditional chemical attachment methods, offering a simpler approach designed to produce higher-quality vaccines targeting bacterial infections
▪The acquisition of Omniose by AstraZeneca followed a three-year exclusive research collaboration between the two companies, with financial terms of the deal undisclosed
▪Omniose's bioconjugation platform enables single E. coli cells to produce and link bacterial polysaccharide antigens to engineered carrier proteins in a single process

Topics

Mergers & acquisitions (M&A)Antimicrobial resistance Mergers and acquisitions Infectious disease Biotech innovation Vaccine development Pharmaceutical Industry Biotechnology Corporate strategy

Related entities

United States St. Louis